Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for treating severe atopic dermatitis by administering an il-4r inhibitor

A technology of atopic dermatitis and inhibitor, applied in the field of treatment of atopic dermatitis, can solve problems such as unsatisfied

Pending Publication Date: 2019-07-02
REGENERON PHARM INC +1
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, there is a clear unmet medical need for alternative treatments for AD, especially severe AD, among candidates for systemic therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
  • Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
  • Methods for treating severe atopic dermatitis by administering an il-4r inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0100] In embodiment 1, the invention includes a method of treating severe atopic dermatitis (AD) comprising: (a) selecting a patient with severe AD, wherein the patient is resistant, inadequately responsive, or intolerant to systemic immunosuppressant therapy and / or when such treatment is not advisable; (b) administering one or more doses of an interleukin 4 receptor (IL-4R) inhibitor to the patient in need.

[0101] In embodiment 2, the invention includes the method of embodiment 1, wherein the treatment is not advisable due to safety and health risks to the patient and suboptimal efficacy.

[0102] In embodiment 3, the invention includes the method of embodiment 1 or 2, wherein the systemic immunosuppressant therapy is selected from the group consisting of cyclosporin A, methotrexate, mycophenolate mofetil, azathioprine, systemic corticosteroids, and interferon- gamma.

[0103] In embodiment 4, the invention includes the method of embodiment 3, wherein the systemic immunos...

Embodiment approach 13

[0112] In embodiment 13, the invention includes a method of treating severe AD comprising: (a) selecting a patient with severe AD, wherein the patient has previously been treated with a drug selected from the group consisting of cyclosporin A, an IgE inhibitor, a TNFα inhibitor, a CD11a inhibitor , CD20 inhibitors, antibiotics, IL-4R inhibitors, dupilumab, systemic immunosuppressants, topical corticosteroids, oral corticosteroids, calcineurin inhibitors, and phototherapy; and (b) as needed The patient is administered one or more doses of an IL-4R inhibitor.

[0113] In embodiment 14, the invention includes the method of embodiment 13, wherein the patient is resistant, underresponsive, or intolerant to the therapeutic agent.

[0114] In embodiment 15, the invention includes the method of embodiment 13 or 14, wherein the treatment is not advisable due to safety and health risks to the patient and suboptimal efficacy.

[0115] In embodiment 16, the invention includes the method ...

Embodiment 1

[0150] Example 1: Anti-IL-4R Antibodies in Adult Patients with Severe Atopic Dermatitis (AD) Insufficiently Controlled with or Intolerant to Cyclosporine A When Treatment Here is Medically Inadvisable clinical trials in

[0151] This is a 32-week double-blind, randomized, placebo-controlled, parallel-group study to confirm the efficacy, safety and tolerability of dupilumab in adults with severe AD. In adults, cyclosporine A (CSA) has not demonstrated sufficient efficacy, has unacceptable side effects, or for whom initial CSA is not medically advisable.

[0152] Dupilumab is a fully human anti-IL-4R antibody, comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:9 and a light chain comprising the amino acid sequence of SEQ ID NO:10; the HCVR / LCVR amino acid sequence pair comprising SEQ ID NO:1 / 2 and heavy and light chain CDR sequences comprising SEQ ID NOs: 3-8.

[0153] The study included a 2-week screening period, a 2-week moderate-power TCS standardizati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one ormore doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present invention are used to treat severe AD in a patient whose disease is not controlled with systemic therapy (e.g., cyclosporine A) or when such therapy is inadvisable.

Description

[0001] sequence statement [0002] This application contains a Sequence Listing that has been filed electronically in ASCII format and is hereby incorporated by reference in its entirety. This ASCII copy, created on September 11, 2017, is named SequenceList_29.TXT and is 10.9 kilobytes in size. technical field [0003] The present invention relates to methods for the treatment of atopic dermatitis. More specifically, the invention relates to the administration of an interleukin-4 receptor (IL-4R) inhibitor in an individual in need thereof. Background technique [0004] Atopic dermatitis (AD) is characterized by severe pruritic (i.e. itching), xerosis (dry skin) and eczematous lesions (characterized by erythema, infiltrates / papules, exudate crusts, exfoliation and lichenification) ) of chronic / relapsing inflammatory skin disease. It is often associated with other atopic disorders such as allergic rhinitis and asthma. Severe illness can be profoundly disabling due to sever...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00A61P17/00
CPCA61K38/00C07K16/2866C07K2317/21C07K2317/76A61K2039/545A61K2039/505C07K2317/90A61K39/395A61K2300/00A61P17/00A61K2039/54A61K38/02A61K9/0019A61K45/06C07K7/06C07K16/247
Inventor A·拉丁N·格拉哈姆B·阿金拉德G·皮罗奇X·孙T·胡尔奇B·S·舒梅尔A·班塞尔
Owner REGENERON PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com